OligoGpivotalCF and Covid-19

AlgiPharma CF Clinical Trial Operations in Europe on hold

Regulatory and ethical approvals have been received from Austria and UK, and approvals are expected to follow soon in Germany and Ireland, allowing to proceed with the OligoGpivotalCF clinical study. However, due to the current situation with COVID-19, it has been decided to postpone site initiation visits until after April 12 (Easter break) to minimize the risk for the CF community.

The Cystic Fibrosis Foundation (CFF) has today issued guidance, based on recommendations from the US CDC and local health authorities, which are relevant here. To learn more about the study, visit www.OligoGpivotalCF.eu

See also https://www.cff.org/Life-With-CF/Daily-Life/Germs-and-Staying-Healthy/What-Are-Germs/COVID-19-Community-Questions-and-Answers/

‹ Terug

Contact information

  • Hilde De Keyser
  • hilde.dekeyser@cf-europe.eu
  • 0032 - (0)2 61 32 716
  • Driebruggenstraat 124, 1160 Brussel
  • Chamber of Commerce number: 0640.670.746

Subscribe to newsletter